Funded Project Details - FY2021
|Title:|| Noradrenergic biomarkers in PTSD: precision medicine & mechanisms|
|Congressional District Code:
||Clinical Science R&D
|| June 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Background and Study Objective: Posttraumatic stress disorder (PTSD) affects as many as 15% of service members and Veterans following deployment. Current treatments are insufficient: most medications for PTSD decrease symptom intensity only moderately, and often appear to be less effective in Veterans than civilians. Prazosin, an antagonist of one of the major receptors for noradrenaline, has demonstrated significant efficacy for particularly hyperarousal symptoms and trauma nightmares in Vetera...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.